Media

Lupin Receives EIR from U.S. FDA for its Somerset Manufacturing Facility

Lupin Announces Closure of US FDA Inspection at its Injectable Facility with Zero 483 Observations

Lupin Launches Doxycycline for Injection USP in the United States

Lupin Receives Tentative Approval from U.S. FDA for Letermovir Tablets

Lupin Receives Approval from U.S. FDA for Midostaurin Capsules

Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.5%

Lupin Receives EIR from U.S. FDA for its Aurangabad Manufacturing Facility

Lupin Launches Mirabegron Extended-Release Tablets in the United States